FDA orders recall of millions of eye drops after detection of foreign bodies

The United States Food and Drug Administration, the FDA, reported this Wednesday, July 9, 2026, that millions of bottles of eye drops widely used to treat allergies and inflammation in the eyes are being withdrawn from the market. The measure was taken due to the possible presence of foreign elements in the product, which generated concern among consumers and health authorities.
The recall specifically covers prednisolone acetate ophthalmic suspension, a medication intended to treat eye conditions. The decision to withdraw was motivated by suspicion of contamination by a foreign substance, as detailed in the official recall statement issued by the authorities.
Lupine Pharmaceuticals Inc., responsible for manufacturing the prescription medicine, is voluntarily recalling more than 2.5 million units of the product. This proactive action by the company aims to ensure patient safety and compliance with the quality standards required by health legislation.
As described by the Mayo Clinic, prednisolone is a steroid widely used to alleviate redness, itching and swelling resulting from infections and other eye conditions. It is essential to highlight that this medicine can only be purchased upon presentation of a medical prescription, highlighting its nature of controlled use and the importance of its integrity.
Medicine recall details
- 5 mL vials (NDC 70748-332-02)
- 10 mL vials (NDC 70748-332-03)
- 15 mL vials (NDC 70748-332-04)
The medicine is manufactured by Lupine Limited, located in Pithampur, India.
The total quantity of products affected by the recall is 2,530,182 bottles, a significant number that reflects the scale of the market withdrawal operation.
The recall identification number, as recorded by authorities, is D-0655-2026.
This recall of eye drops involves dozens of different batch codes and bottle types, impacting a wide range of products distributed. It is recommended that patients check their medications to confirm whether they are affected.
The FDA classified the recall as Class II. This category indicates that use or exposure to the product may result in adverse health consequences that are, in most cases, temporary or medically reversible, although they require attention.
Lupine Pharmaceuticals Inc. was approached for comment on the matter, but was not immediately available to comment on the recall of the vials.






